C5 and paroxysmal nocturnal hemoglobinuria: The terminal complement component 5 (C5) inhibitors (C5is) eculizumab (Soliris®, Alexion Pharmaceuticals Inc.)and ravulizumab (Ultomiris®, Alexion Pharmaceuticals Inc.)have revolutionized treatment outcomes for patients with PNH.